Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberCA2397654 A1
Publication typeApplication
Application numberCA 2397654
PCT numberPCT/US2001/002061
Publication date26 Jul 2001
Filing date18 Jan 2001
Priority date20 Jan 2000
Also published asCA2397654C, DE60035404D1, DE60035404T2, EP1121945A1, EP1121945B1, EP1767229A2, EP1767229A3, EP1767229B1, EP2301592A1, EP2301592B1, US6355063, US20020091440, WO2001052914A1
Publication numberCA 2397654, CA 2397654 A1, CA 2397654A1, CA-A1-2397654, CA2397654 A1, CA2397654A1, PCT/2001/2061, PCT/US/1/002061, PCT/US/1/02061, PCT/US/2001/002061, PCT/US/2001/02061, PCT/US1/002061, PCT/US1/02061, PCT/US1002061, PCT/US102061, PCT/US2001/002061, PCT/US2001/02061, PCT/US2001002061, PCT/US200102061
InventorsRobert W. Calcote
ApplicantRobert W. Calcote, Impra, Inc. A Subsidiary Of C.R. Bard, Inc., Bard Peripheral Vascular, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: CIPO, Espacenet
Expanded ptfe drug delivery graft
CA 2397654 A1
Abstract
An improved ePTFE-based delivery graft is intended to dispense a bioactive agent such as a drug into the blood stream. A hollow tubing is infused with the agent from a source such as a drug delivery pump mechanism. The spiral hollow tubing is wrapped in a helical fashion around, or otherwise brought into contact with an outer wall of a porous ePTFE graft and adhered thereto.
The agent is delivered to the lumen of the graft by infusing the agent through the porous interstices of the graft wall. Thus, the bioactive agent is conducted by the hollow tubing from a source to the outer surface of an ePTFE
graft where it is released to diffuse into the graft to influence biological processes along both the inner and outer surfaces of the graft. The present invention allows the bioactive agent or drug to be renewed or changed after implant of the graft. In addition the present invention can be implanted in the same fashion as regular vascular grafts.
Description  available in
Claims(25)
1. A drug delivery graft comprising:
a graft having a lumen and a porous wall; and a hollow tubing having a bore, running along an exterior surface of said graft in fluid communication with said porous wall of said graft, wherein a drug can be infused into said bore of said hollow tubing to penetrate into said lumen of said graft through said porous wall.
2. The drug delivery graft of Claim 1 further comprising a drug source attached to one end of said hollow tubing.
3. The drug delivery graft of Claim 1, wherein said hollow tube is wrapped helically around the outer surface of said graft.
4. The drug delivery graft of Claim 1, wherein said hollow tube is arranged substantially parallel to a longitudinal axis of said graft.
5. The drug delivery graft of Claim 1, wherein said graft comprises ePTFE.
6. The drug delivery graft of Claim 1, wherein said hollow tubing comprises a cutaway portion in contact with said porous wall of said graft.
7. The drug delivery graft of Claim 1, wherein said hollow tubing comprises perforations communicating said bore of said hollow tubing with said porous wall of said graft.
8. The drug delivery graft of Claim 1, wherein said hollow tubing comprises a porous wall allowing fluid communication with said porous wall of said graft.
9. The drug delivery graft of Claim 2, wherein said drug source further comprises a drug delivery pump.
10. The drug delivery graft of Claim 2, wherein said drug is selected to prevent restenosis of a blood vessel.
11. The drug delivery graft of Claim 10, wherein said drug is selected from the group consisting of a growth factor, a growth factor inhibitor, growth factor receptor antagonist, a transcriptional repressor, a translational repressor, an antisense nucleic acid, a replication inhibitor, an anti-microtubule agent, an inhibitory antibody, an antibody directed against a growth factor, a bifunctional molecules comprising a growth factor and a cytotoxin, and a bifunctional molecule comprising an antibody and a cytotoxin.
12. A drug delivery device comprising:
porous graft means for replacing a natural tissue conduit; and hollow tubing means in contact with an outer surface of said porous graft means for delivering a drug to said porous graft means via areas in contact with said porous graft means.
13. The drug delivery device of Claim 12, wherein the hollow tubing means is wrapped helically about said porous graft means.
14. The drug delivery device of Claim 12 further comprising drug infusing means for infusing said drug into said hollow tubing means.
15. The drug delivery device of Claim 12, wherein said areas in communication with said porous graft means comprise a cutaway section.
16. The drug delivery device of Claim 12, wherein said areas in communication with said porous graft means comprise perforations on said hollow tubing means.
17. The drug delivery device of Claim 12, wherein said areas in communication with said porous graft means comprise a porous region on said hollow tubing means.
18. A drug delivery system manufactured by a process comprising the steps of:
providing a porous graft;
providing a small diameter hollow tubing having defined porous areas;
bringing said small diameter hollow tubing into contact with said porous graft such that said defined porous areas are secured against an outer surface of the porous graft; and connecting an end of the small diameter beading to a drug source so that a drug from the drug source enters said small diameter hollow tubing and passes through the porous areas into said porous graft.
19. The drug delivery system of Claim 18, wherein said small diameter hollow tubing is wrapped helically about said porous graft.
20. The drug delivery system of Claim 18, wherein said defined porous areas of said small diameter hollow tubing comprise cut away sections of said small diameter hollow tubing.
21. The drug delivery system of Claim 18, wherein said process further comprises the step of using a cutting device to cut said defined porous areas into said small diameter hollow tubing.
22. The drug delivery system of Claim 18, wherein said defined porous areas of said small diameter hollow tubing further comprise perforations on said small diameter hollow tubing.
23. The drug delivery system of Claim 18, wherein said connecting step further comprises connecting said unsealed end of said small diameter hollow tubing to a drug infusion pump.
24. A method of preventing restenosis of a blood vessel comprising the steps of:
providing a porous graft ;
providing a small diameter hollow tubing in contact with said graft and having a porous region in fluid communication with an outer surface of said porous graft;
connecting an end of said small diameter hollow tubing to an anti-restenosis agent source;
delivering said anti-restenosis agent to said blood vessel via said small diameter hollow tubing and said porous graft.
25. The method of Claim 24, wherein said anti-restenosis agent is selected from the group consisting of a growth factor, a growth factor inhibitor, growth factor receptor antagonist, a transcriptional repressor, a translational repressor, an antisense nucleic acid, a replication inhibitor, an anti-microtubule agent, an inhibitory antibody, an antibody directed against a growth factor, a bifunctional molecules comprising a growth factor and a cytotoxin, and a bifunctional molecule comprising an antibody and a cytotoxin.
Classifications
International ClassificationA61L27/54, A61L31/16, A61L31/04, A61L27/16, A61F2/06
Cooperative ClassificationA61L31/16, A61L27/54, A61F2/06, A61L31/048, A61L2300/00, A61L2300/416, A61F2250/0068, A61L27/16
European ClassificationA61L27/16, A61L31/04H, A61F2/06, A61L31/16, A61L27/54
Legal Events
DateCodeEventDescription
21 Dec 2005EEERExamination request